Clinical Trial Results: Positive data from trials of leronlimab, CYDY's main drug, typically boosts the stock price, while negative data leads to declines.

Regulatory Approvals: FDA approval of leronlimab for any indication would likely cause a significant surge in the stock price.

Financial Performance: CYDY's cash position, debt levels, and ability to secure funding impact investor confidence and the stock price.

Market Sentiment: Overall market conditions, investor risk appetite, and sector-specific trends (e.g., biotechnology) can influence CYDY's stock.

Competition: The presence of competing drugs or therapies for the same indications as leronlimab can negatively impact the stock.

Partnerships and Collaborations: Announcements of partnerships with other pharmaceutical companies or research institutions often positively affect the stock.

News and Media Coverage: Positive or negative news articles, social media discussions, and analyst ratings can influence investor sentiment and trading activity.

Management Changes: Changes in the company's leadership or board of directors can sometimes impact investor confidence and stock performance.

Intellectual Property: The strength and validity of CYDY's patents related to leronlimab are crucial for its long-term value and stock price.

Manufacturing and Supply Chain: Any disruptions in the manufacturing or supply chain of leronlimab could negatively impact the stock price.